|Videos|May 26, 2017

Infectious Disease Outbreaks: What We Need to Know

Arjun Srinivasan, MD, explains the most important thing that individuals need to know regarding outbreaks.

Arjun Srinivasan, MD, associate director, Healthcare-associated Infection Prevention Programs, Centers for Disease Control and Prevention, explains the most important thing that individuals need to know regarding outbreaks.

Interview Transcript (slightly modified for readability)

“The most important thing that I think people need to know about outbreaks is that they do happen; they are a reality in healthcare settings. They are something that we are always working hard to try and prevent, and just as importantly, we work very hard to detect them and to investigate them. These are situations that we always have to take very seriously, that we have to investigate, and they are situations that we need to learn from. A lot of what we know about preventing infections comes from investigating outbreaks, and so, it’s important that we investigate those outbreaks and then use that information [of] what we learn from an outbreak, to try and make healthcare safer for the next people.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.